Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer).
Authors: Pogue-Geile, K.L., Andre, T., Song, N., Lipchik, C., Wang, Y., Kim, R.S., Feng, H., Gavin, P., Van Laethem, J.-L., Srinivasan, A., Hickish, T., Jacobs, S.A., Tabernero, J., Lucas, P.C., De Gramont, A., Wolmark, N., Flejou, J.-F., Paik, S.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Publication Date: 20/05/2019
Volume: 37
Issue: 15
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/JCO.2019.37.15_suppl.3503
Source: Web of Science